The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer is a major global health concern, with abnormal activation of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway implicated in carcinogenesis.
• Cytokines act as cancer drivers by utilizing the JAK-STAT pathway for cellular communication, and genetic variations in this system are linked to cancer risk.

Purpose of the Study:

• To summarize the role of Janus kinases (JAKs) in regulating STAT activity.
• To highlight JAK inhibitors as a potential therapeutic strategy for solid tumors by targeting the JAK-STAT pathway.

Main Methods:

• Review of preclinical investigations on JAK inhibitors in solid tumor cell line models.
• Analysis of studies evaluating JAK inhibitors in combination with other cancer therapies.
• Examination of ongoing and completed clinical trials involving JAK antagonists.

Main Results:

• Preclinical studies demonstrate that JAK inhibitors can reduce STAT signaling, proliferation, and survival in solid tumor models.
• JAK inhibitors, such as ruxolitinib, enhance the efficacy of radiotherapy, biological response modifiers, and oncolytic viruses in preclinical models.
• Numerous JAK antagonists are under investigation in clinical trials for cancer treatment, both as monotherapy and in combination regimens.

Conclusions:

• JAK inhibition presents a promising strategy for targeting the JAK-STAT pathway in solid tumors.
• While preclinical data is encouraging, further clinical trials are essential to establish the efficacy of JAK inhibitors in solid tumor treatment.
• Understanding JAK's role as an upstream regulator of STATs can aid in the development of more targeted anti-cancer drug molecules.